Ventricular resynchronization is the principle mechanism of benefit with cardiac resynchronization therapy

John Gorcsan1, Cheuk-Man Yu, John E Sanderson

  • 1University of Pittsburgh, Scaife 564, 200 Lothrop Street, Pittsburgh, PA 15213-2582, USA. gorcsanj@upmc.edu

Heart Failure Reviews
|July 26, 2011
PubMed

Insights

Cardiac resynchronization therapy (CRT) improves heart function by addressing mechanical dyssynchrony. Patients with significant electrical delays but no mechanical issues may not benefit as much from CRT.

Area of Science:

  • Cardiology
  • Biomedical Engineering

Background:

  • Cardiac resynchronization therapy (CRT) benefits many patients with heart failure.
  • Patient selection for CRT typically relies on QRS widening, but the precise mechanism of benefit remains debated.
  • A significant portion of patients with widened QRS complexes lack mechanical dyssynchrony.

Purpose of the Study:

  • To investigate the role of mechanical dyssynchrony as a predictor of CRT response.
  • To explore the relationship between electrical dispersion and mechanical dyssynchrony in CRT outcomes.
  • To clarify the mechanistic basis for CRT benefits.

Main Methods:

  • Review of existing literature and imaging studies (primarily echocardiography).
  • Analysis of patient data correlating baseline mechanical dyssynchrony with CRT outcomes.
  • Examination of studies assessing changes in mechanical dyssynchrony post-CRT.

Main Results:

  • A substantial subset of patients with QRS widening exhibit no significant mechanical dyssynchrony.
  • Lack of baseline mechanical dyssynchrony is associated with less favorable outcomes after CRT.
  • Absence of improved mechanical dyssynchrony post-CRT correlates with reduced reverse remodeling and poorer long-term prognosis.

Conclusions:

  • Mechanical dyssynchrony, rather than just QRS widening, is a critical factor for CRT efficacy.
  • Identifying and addressing mechanical dyssynchrony is crucial for optimizing CRT patient selection and outcomes.
  • Resynchronization of mechanical activation is the primary mechanism driving CRT benefits.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...